📋 Key Information Summary
- Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60–70% of all dementia cases in Australia, with an estimated 400,000+ Australians currently living with dementia.
- Typical presentation begins with progressive episodic memory impairment (difficulty learning new information), later expanding to multidomain cognitive decline involving language, visuospatial skills, and executive function.
- Structured staging using the Clinical Dementia Rating (CDR) scale or GDS guides prognosis, treatment decisions, and care planning across mild cognitive impairment (MCI), mild, moderate, and severe stages.
- Diagnosis requires comprehensive history (ideally with an informant), cognitive screening (MoCA or MMSE), functional assessment, blood work to exclude reversible causes, and structural brain imaging (MRI preferred).
- Amyloid PET and CSF biomarkers (Aβ42/40 ratio, p-tau181, p-tau217) are now used to confirm amyloid pathology, especially in atypical or early-onset presentations; plasma p-tau217 assays are emerging in Australian practice.
- Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are first-line pharmacotherapy for mild-to-moderate AD and are PBS-listed under Authority Required for confirmed diagnosis.
- Memantine (NMDA receptor antagonist) is indicated for moderate-to-severe AD and may be combined with a cholinesterase inhibitor; it is PBS-listed under Authority Required.
- Anti-amyloid monoclonal antibodies (lecanemab, donanemab) slow decline in early AD; lecanemab (Leqembi®) received TGA approval in 2024 but is not yet PBS-listed — access via clinical trials or private prescription, with mandatory ARIA monitoring.
- Behavioural and psychological symptoms of dementia (BPSD) affect up to 90% of people with AD; non-pharmacological strategies are first-line, with antipsychotics reserved for severe agitation or psychosis posing safety risk.
- Atypical antipsychotics (risperidone) carry black-box warnings of increased mortality in elderly dementia patients — use lowest dose for shortest duration, with documented informed consent and regular review.
- Carer burden is substantial: up to 50% of primary caregivers experience clinically significant depression — systematic psychosocial support, respite care, and referral to Dementia Australia are essential components of management.
- Aboriginal and Torres Strait Islander Australians experience dementia at 3–5 times the age-standardised rate of non-Indigenous Australians, often with earlier onset; culturally safe assessment tools and community-based care models are critical.
- Address reversible contributors (depression, B12 deficiency, hypothyroidism, medications with anticholinergic burden) and optimise cardiovascular risk factors as part of a brain health and risk reduction strategy.
Introduction & Australian Epidemiology
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the single most common cause of dementia worldwide. In Australia, dementia affects an estimated 421,000 people (2024 AIHW figures), with AD responsible for approximately 60–70% of cases. The condition is characterised by insidious onset and gradual decline in cognitive function, most commonly beginning with episodic memory impairment before progressing to affect language, visuospatial processing, executive function, and behaviour.
AD places a significant burden on the Australian healthcare system. The total cost of dementia in Australia is estimated at over billion annually (AIHW, 2023). Dementia is the second leading cause of death in Australia and the leading cause of death among women. With an ageing population, prevalence is projected to exceed 800,000 by 2054.
Early and accurate diagnosis enables timely initiation of symptomatic therapies, advance care planning, caregiver education, and — increasingly — access to disease-modifying treatments. A structured approach to assessment, staging, pharmacotherapy, and psychosocial support is essential for optimal patient and carer outcomes.
Diagnostic imperative: Up to 30–50% of dementia cases in Australia remain undiagnosed. Under-recognition delays access to treatment, support services, advance care planning, and driving assessment. General practitioners are encouraged to screen for cognitive decline in patients aged ≥65 years using validated tools (MoCA, MMSE, GP-COG) when concerns are raised by the patient, family, or clinical observation.
Key Australian Statistics
- Prevalence: ~421,000 Australians living with dementia (2024); projected 812,500 by 2054.
- Incidence: ~28,000 new cases per year (aged ≥65 years).
- Age-specific prevalence: ~3% in 65–74 years, ~12% in 75–84 years, ~33% in ≥85 years.
- Aboriginal and Torres Strait Islander Australians: dementia prevalence 3–5× age-adjusted rate, with onset often 10 years earlier.
- Women represent approximately 64% of all people living with dementia.
- Younger-onset dementia (<65 years): ~28,000 Australians, with AD accounting for approximately one-third of cases.
Clinical Features and Staging
Core Clinical Features
AD presents with an insidious and progressive decline in cognitive function. The hallmark is impairment in episodic memory (difficulty learning and recalling new information), which typically precedes deficits in other cognitive domains. A reliable informant history is essential — patients often lack insight into their deficits.
Typical (amnestic) presentation: Begins with difficulty recalling recent events, repeating questions, misplacing items, and struggling with appointments. Language difficulties (word-finding), visuospatial disorientation (getting lost in familiar places), and executive dysfunction (impaired planning, judgement, multitasking) emerge as the disease progresses.
Cognitive Domains Affected
| Domain | Early Features | Later Features |
|---|---|---|
| Episodic memory | Difficulty learning new information, repeating questions | Forgetting family names, personal history |
| Language | Word-finding difficulties, reduced verbal fluency | Aphasia, echolalia, mutism |
| Visuospatial | Difficulty navigating, spatial disorientation | Cannot recognise faces, dressing apraxia |
| Executive function | Impaired planning, multitasking, financial management | Severe apraxia, abulia |
| Attention | Reduced divided attention | Disorientation to time, place, person |
| Behaviour/mood | Apathy, mild irritability, withdrawal | Agitation, psychosis, aggression |
Staging — Clinical Dementia Rating (CDR) Scale
MCI
Mild Cognitive Impairment (CDR 0.5)
Subjective cognitive complaint with objective evidence on testing. Independence in functional activities preserved. Does not meet criteria for dementia. Conversion rate to AD: ~10–15% per year.
Setting: GP with specialist review; consider cholinesterase inhibitor trial
Mild
Mild AD (CDR 1)
Memory deficits interfere with daily function. Difficulty managing finances, medications, appointments. Word-finding and navigation difficulties. Mood changes, mild apathy. Still largely independent with some supervision.
Setting: Outpatient geriatrician / neurologist; initiate cholinesterase inhibitor
Moderate
Moderate AD (CDR 2)
Significant cognitive and functional decline. Requires assistance with ADLs (dressing, bathing, toileting). Increasing BPSD — agitation, wandering, sundowning, possible psychosis. Language significantly impaired. May not recognise family.
Setting: Home with supports / residential care consideration; add memantine
Severe
Severe AD (CDR 3)
Near-total dependence. Minimal verbal communication. Incontinence. Dysphagia. Immobility. Contractures. Seizures may occur. Risk of aspiration pneumonia, pressure injuries, malnutrition. End-of-life planning essential.
Setting: Residential aged care / palliative care
Atypical AD Variants
- Posterior cortical atrophy (PCA): Visuospatial and visuoperceptual deficits prominent early (simultagnosia, optic atalexia, Gerstmann syndrome). Memory relatively preserved initially. Often younger onset (50s–60s).
- Logopenic variant primary progressive aphasia (lvPPA): Progressive word-finding difficulty and impaired sentence repetition with relatively preserved single-word comprehension and object knowledge.
- Frontal/behavioural variant AD: Executive dysfunction, personality change, apathy, and disinhibition prominent — may mimic frontotemporal dementia. Confirmed by amyloid biomarkers.
Biomarkers and Imaging
Structural Neuroimaging
Structural brain imaging is recommended for all patients being assessed for suspected dementia. MRI is preferred over CT when available and safe (e.g., no contraindications). Imaging serves to exclude treatable causes (subdural haematoma, hydrocephalus, stroke, tumour) and to identify patterns of atrophy consistent with AD.
Essential
MRI Brain (with coronal hippocampal slices)
Medial temporal lobe atrophy (MTA) scoring (Scheltens scale 0–4). Hippocampal volume loss is characteristic. Posterior atrophy suggests PCA variant. MBS Item 63076 (GP referral to radiology). Available in all major centres; telehealth review possible for regional areas.
Available
CT Brain (non-contrast)
Acceptable when MRI contraindicated. Less sensitive for early atrophy but adequate for excluding structural pathology. MBS Item 56001.
Available
FDG-PET (18F-fluorodeoxyglucose PET)
Demonstrates temporoparietal hypometabolism characteristic of AD. Useful in differentiating AD from frontotemporal dementia. MBS Item 61423 (restricted — specialist referral). Available in metropolitan centres.
Molecular Biomarkers — Amyloid and Tau
Amyloid and tau biomarkers can confirm AD pathology in vivo. They are increasingly used in clinical practice for diagnostic certainty, particularly in atypical presentations, and are now required for eligibility for anti-amyloid disease-modifying therapies.
| Biomarker | Modality | Interpretation | Australian Availability |
|---|---|---|---|
| Amyloid PET | ¹⁸F-florbetapir (Amyvid), ¹⁸F-flutemetamol (Vizamyl), ¹⁸F-florbetaben (Neuraceq) | Positive cortical uptake = amyloid plaque presence. High sensitivity (~96%) for AD pathology. | Available in major capital cities (Sydney, Melbourne, Brisbane, Adelaide, Perth). Not MBS-listed; cost ~,000–4,500. PETARA sites may offer subsidised access. |
| CSF Aβ42/40 ratio | Lumbar puncture — CSF analysis | Reduced ratio indicates amyloid deposition. Sensitivity ~85–90%. | Available through specialist neurology/geriatrics departments. MBS Item 65090 (LP). CSF sent to reference labs (Sullivan Nicolaides, Douglass Hanly Moir). |
| CSF p-tau181 / p-tau217 | Lumbar puncture — CSF analysis | Elevated tau correlates with neurodegeneration and AD tauopathy. | Available via reference laboratories; increasingly included in AD CSF panels. |
| Plasma p-tau217 | Blood test | Emerging as a highly accurate screening blood test (AUC ~0.95). Positive predictive value increases when combined with Aβ42/40 ratio. May reduce need for PET/CSF in some patients. | Not yet standard clinical pathology in Australia (2025). Available through research trials and specialised memory clinics. Expected to enter clinical use in 2025–2026. |
| CSF neurofilament light (NfL) | Lumbar puncture or blood (serum) | Non-specific marker of neuronal damage. Elevated in AD and other neurodegenerative conditions. Useful for prognosis and monitoring. | Research and specialised clinic use; not routine MBS-listed. |
ATN classification framework: The 2018 NIA-AA Research Framework classifies AD biologically using the ATN system — Amyloid (CSF Aβ42 or amyloid PET), Tau (CSF p-tau or tau PET), and Neurodegeneration (FDG-PET, hippocampal atrophy, or CSF total tau). This moves AD diagnosis from syndromic to biological criteria.
Blood Tests to Exclude Reversible Causes
Essential
FBC, ESR, CRP, UEC, LFTs, TFTs (TSH, free T4)
Exclude anaemia, infection, renal failure, hepatic encephalopathy, hypothyroidism. MBS items under standard pathology referral.
Essential
Vitamin B12, folate
B12 deficiency is a reversible cause of cognitive decline and common in elderly Australians. MBS Item 66832.
Available
Syphilis serology, HIV testing
Consider in younger patients or those with risk factors. Neurosyphilis and HIV-associated neurocognitive disorder are treatable.
Available
Calcium, glucose (fasting/HbA1c), vitamin D
Hypercalcaemia, uncontrolled diabetes, and severe vitamin D deficiency may contribute to cognitive impairment.
Pathophysiology
Alzheimer's disease is defined by two hallmark neuropathological features: extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. The amyloid cascade hypothesis, though debated in detail, remains central to understanding AD pathogenesis and informs current disease-modifying therapeutic strategies.
Amyloid Cascade
- Amyloid precursor protein (APP) processing: APP is cleaved by β-secretase (BACE1) and γ-secretase to produce Aβ peptides. The Aβ42 isoform is more aggregation-prone and neurotoxic than Aβ40.
- Plaque formation: Monomeric Aβ42 oligomerises, then forms insoluble fibrils and diffuse/neuritic plaques. Soluble oligomers are considered the most neurotoxic species.
- Downstream tau pathology: Aβ accumulation triggers tau hyperphosphorylation via kinase activation. Phosphorylated tau detaches from microtubules, aggregates into paired helical filaments, and forms neurofibrillary tangles, causing neuronal death.
Contributing Mechanisms
- Neuroinflammation: Microglial activation and astrocyte reactivity amplify neuronal damage. Complement activation and cytokine release perpetuate chronic inflammation.
- Cholinergic deficit: Loss of cholinergic neurons in the nucleus basalis of Meynert reduces cortical acetylcholine, contributing to attention and memory deficits — the basis for cholinesterase inhibitor therapy.
- Glutamate excitotoxicity: Excessive NMDA receptor activation leads to calcium influx and neuronal death — the target for memantine therapy.
- Oxidative stress and mitochondrial dysfunction: Impaired energy metabolism and reactive oxygen species generation contribute to neuronal vulnerability.
- Vascular contributions: Cerebrovascular disease, blood–brain barrier breakdown, and cerebral amyloid angiopathy frequently co-exist with AD pathology and worsen outcomes.
Genetic Factors
| Category | Genes | Details |
|---|---|---|
| Autosomal dominant (familial, <1%) | APP, PSEN1, PSEN2 | Usually onset <65 years. PSEN1 most common. Near 100% penetrance. Refer for genetic counselling. |
| Risk gene (strongest) | APOE ε4 allele | Heterozygous ε4: 3–4× risk. Homozygous ε4: 8–15× risk. Also associated with increased ARIA risk with anti-amyloid therapies. Not deterministic — population screening not recommended. |
| Protective variant | APOE ε2, APOE Christchurch | ε2 associated with reduced AD risk. Christchurch mutation (R136S in APOE3) described in a case with PSEN1 mutation with delayed onset by ~30 years. |
| Common risk variants (GWAS) | TREM2, CLU, BIN1, PICALM, CD33, ABCA7, SORL1 >75 loci | Each confers small individual risk. Polygenic risk scores under research. Implicated in immune function, lipid metabolism, endocytosis. |
Neuropathological Staging (Braak)
- Braak I–II (transentorhinal): Tau pathology confined to entorhinal cortex and hippocampus. Correlates with earliest memory symptoms (MCI).
- Braak III–IV (limbic): Extension to amygdala, thalamus, basal forebrain. Correlates with mild-to-moderate AD clinically.
- Braak V–VI (isocortical): Widespread neocortical tau involvement. Correlates with severe AD and global cognitive impairment.
Cognitive Enhancers and Disease-Modifying Therapies
Cholinesterase Inhibitors (ChEIs) — Mild-to-Moderate AD
Cholinesterase inhibitors increase synaptic acetylcholine availability by inhibiting its enzymatic breakdown. They provide modest symptomatic benefit in cognitive function, activities of daily living, and global clinical impression. NNT ≈ 12 for clinically meaningful improvement at 6 months. They do not alter disease trajectory but provide a period of stabilisation.
Donepezil
Aricept® · Generic available · Acetylcholinesterase inhibitor
Adult dose
5 mg PO nocte for 4–6 weeks → increase to 10 mg PO nocte. 23 mg tablet available for moderate–severe AD (limited evidence). ODT formulation available.
Paediatric dose
Not indicated (paediatric AD exceptionally rare)
Renal adjustment
No adjustment required
Hepatic adjustment
Use with caution in significant hepatic impairment (CYP2D6/3A4 substrate); no specific dose guidance
Key interactions
CYP2D6 inhibitors (paroxetine, fluoxetine) may increase levels. Avoid with other cholinomimetics. May exacerbate bradycardia with β-blockers.
Common side effects
Nausea, diarrhoea, insomnia, muscle cramps, anorexia — usually transient
PBS status
Authority Required (STREAMLINED 10200) — Initial and continuing treatment for Alzheimer's disease confirmed by specialist
Rivastigmine
Exelon® · Generic available · Acetylcholinesterase + butyrylcholinesterase inhibitor
Adult dose (oral)
1.5 mg PO BD with food → increase by 1.5 mg BD every 2 weeks → target 6 mg BD (max 12 mg/day). Start 3 mg BD if tolerated at 4 weeks.
Adult dose (transdermal)
Patch 4.6 mg/24 hours for 4 weeks → 9.5 mg/24 hours → 13.3 mg/24 hours if needed. Change patch daily, rotate sites. Better GI tolerability than oral.
Renal adjustment
No adjustment required
Hepatic adjustment
Use with caution in significant hepatic impairment; monitor closely
Common side effects
Nausea, vomiting, diarrhoea (particularly oral formulation), weight loss. Transdermal patch significantly reduces GI effects.
PBS status
Authority Required (STREAMLINED 10201) — Alzheimer's disease confirmed by specialist
Galantamine
Reminyl® · Generic available · Acetylcholinesterase inhibitor + allosteric nicotinic receptor modulator
Adult dose
4 mg PO mane with food for 4 weeks → 8 mg mane for 4 weeks → 12 mg mane (target). Max 24 mg/day (or 16 mg/day modified-release). MR capsule available (once daily).
Renal adjustment
eGFR 30–59 mL/min: max 16 mg/day. eGFR <30: avoid.
Hepatic adjustment
Child-Pugh A (mild): max 16 mg/day. Child-Pugh B–C: avoid.
Common side effects
Nausea, vomiting, anorexia, weight loss, dizziness
PBS status
Authority Required (STREAMLINED 10202) — Alzheimer's disease confirmed by specialist
Cholinesterase inhibitor initiation: In Australia, PBS Authority requires a diagnosis of Alzheimer's disease confirmed by a specialist (geriatrician, neurologist, psychogeriatrician). GPs can prescribe under specialist advice and manage ongoing therapy. Re-assess response at 3–6 months; cognitive stabilisation is a positive outcome — do not discontinue simply because "improvement" is not seen.
NMDA Receptor Antagonist — Moderate-to-Severe AD
Memantine
Ebixa® · Generic available · NMDA receptor antagonist
Adult dose
5 mg PO mane for 1 week → 10 mg/day (5 mg BD or 10 mg mane) → 15 mg/day → target 20 mg/day (10 mg BD). Titrate weekly.
Renal adjustment
eGFR 30–49 mL/min: max 10 mg/day (5 mg BD). eGFR 5–29 mL/min: 5 mg/day (or alternate day). Avoid if eGFR <5.
Hepatic adjustment
No dose adjustment; use with caution (primarily renally cleared)
Key notes
Can be combined with cholinesterase inhibitor (donepezil most common combination). Indicated for moderate-to-severe AD. Generally well tolerated — dizziness, headache, constipation most common.
PBS status
Authority Required (STREAMLINED 10203) — Moderate-to-severe Alzheimer's disease confirmed by specialist; may be co-prescribed with a ChEI
Disease-Modifying Therapies — Anti-Amyloid Monoclonal Antibodies
A new era of disease-modifying therapy has begun with the approval of anti-amyloid monoclonal antibodies that target and clear amyloid-β plaques from the brain. These agents slow clinical decline in early-stage AD but carry significant safety considerations, most notably amyloid-related imaging abnormalities (ARIA).
Lecanemab
Leqembi® · Eisai/Biogen · Anti-amyloid monoclonal antibody (IgG1)
Indication
Early AD (MCI or mild dementia due to AD) with confirmed amyloid pathology (amyloid PET or CSF biomarker). TGA-approved in Australia (2024).
Adult dose
10 mg/kg IV infusion over ~1 hour, every 2 weeks. Continue indefinitely while clinical benefit persists and amyloid cleared.
Efficacy
Clarity AD trial: 27% slowing of cognitive decline (CDR-SB) at 18 months vs placebo. Amyloid clearance (centiloid reduction) in ~70% of patients.
Key risks
ARIA-E (oedema/effusion): ~12.6% overall; ARIA-H (microhaemorrhage): ~17.3%. Most ARIA is asymptomatic; symptomatic ARIA ~2.8%. APOE ε4 homozygotes at highest risk (~35% ARIA-E). Fatal intracerebral haemorrhage reported rarely, particularly in patients on anticoagulants.
Monitoring
MRI brain at baseline, before 5th infusion (~week 14), before 7th infusion (~week 22), and as clinically indicated. APOE genotyping strongly recommended before treatment.
Exclusions
Anticoagulant therapy (relative contraindication), ≥5 microhaemorrhages on baseline MRI, APOE ε4/ε4 homozygotes (relative — increased ARIA risk, individualised risk-benefit discussion). History of stroke/TIA requires careful assessment.
PBS status
Not PBS-listed — Available via private prescription or clinical trials (2025). Cost approximately ,000–40,000/year. Access and reimbursement pathways under development.
Donanemab
Kisunla® · Eli Lilly · Anti-amyloid monoclonal antibody (targets N-truncated pyroglutamate Aβ)
Indication
Early symptomatic AD with confirmed amyloid and tau pathology. TGA submission under review in Australia (as of 2025).
Adult dose
700 mg IV for first 3 doses → 1400 mg IV every 4 weeks. Treatment can stop once amyloid cleared (amyloid PET negative on protocol-specified imaging). Fixed-duration treatment model.
Efficacy
TRAILBLAZER-ALZ 2: 35% slowing of decline (iADRS) at 18 months in low/medium tau population. 40% of participants met amyloid clearance criteria at 12 months.
Key risks
ARIA-E: ~24%; ARIA-H: ~31%. Three deaths attributed to ARIA-related intracerebral haemorrhage in the trial. APOE ε4/ε4 risk highest.
PBS status
Not TGA-approved / Not PBS-listed (anticipated 2025–2026)
Safety-critical: ARIA monitoring for anti-amyloid therapies. ARIA (amyloid-related imaging abnormalities) includes brain oedema (ARIA-E) and microhaemorrhages (ARIA-H). Most cases are asymptomatic and detected on surveillance MRI, but symptomatic cases can present with headache, confusion, visual disturbance, or rarely, life-threatening intracerebral haemorrhage. Mandatory MRI monitoring, APOE genotyping, and specialist-led treatment in a centre with neuroimaging capacity are required. These therapies are contraindicated in patients on therapeutic anticoagulation (warfarin, DOACs).
Quick Reference — AD Pharmacotherapy Comparison
ChEI monotherapy (mild–moderate AD)
Donepezil, rivastigmine, or galantamine
Ongoing — continue while tolerated and beneficial
Reassess at 3–6 months. Stabilisation = success.
ChEI + memantine (moderate–severe)
Donepezil 10 mg + memantine 20 mg/day
Ongoing
Best evidence for combination in moderate–severe AD
Anti-amyloid DMT (early AD, amyloid-positive)
Lecanemab 10 mg/kg IV q2w
Ongoing until amyloid cleared or discontinuation criteria met
Specialist-only initiation; MRI monitoring mandatory
Supportive and Non-Pharmacological Cognitive Interventions
- Cognitive stimulation therapy (CST): Group-based programme (typically 14 sessions over 7 weeks). Improves cognition and well-being. Widely available in Australian aged-care settings. Endorsed by Dementia Australia.
- Physical exercise: Regular aerobic exercise (≥150 min/week moderate intensity) may slow cognitive decline and improve mood. Strong evidence base for overall brain health.
- Occupational therapy: Environmental modification, routine establishment, activity adaptation. Referral via MBS Item 10958 (Chronic Disease Management plan).
- Neuropsychological rehabilitation: Compensatory strategies, memory aids, goal-setting. Best delivered by clinical neuropsychologist.
- Social engagement and meaningful activity: Maintaining social connections and purposeful activity reduces BPSD and improves quality of life.
BPSD and Caregiver Support
Behavioural and Psychological Symptoms of Dementia (BPSD)
BPSD encompass the non-cognitive neuropsychiatric symptoms that occur in people with dementia. They affect up to 90% of individuals over the course of AD and are the leading cause of caregiver distress, premature residential care placement, and hospitalisation. BPSD are not an inevitable part of dementia — they often reflect unmet needs, pain, environmental factors, or co-existing medical conditions.
| Symptom Domain | Examples | Triggers to Consider |
|---|---|---|
| Psychosis | Hallucinations (visual most common), delusions (theft, infidelity, phantom boarder) | Sensory impairment, medications (anticholinergic burden), infection |
| Agitation/Aggression | Verbal aggression, physical aggression, restlessness | Pain, constipation, urinary retention, overstimulation, unmet need |
| Depression | Low mood, withdrawal, tearfulness, anhedonia | Loss of function, social isolation, medication effects |
| Anxiety | Worry, restlessness, clinginess, separation anxiety | Environmental change, unfamiliar caregivers, pain |
| Apathy | Loss of motivation, reduced initiation, social withdrawal | Most common BPSD; may be under-recognised as depression |
| Sleep disturbance | Sundowning, fragmented sleep, nocturnal wandering | Pain, environmental lighting, medication (diuretics nocte, sedatives daytime) |
| Wandering | Elopement, aimless walking, repetitive pacing | Boredom, pain, searching for something familiar |
| Appetite changes | Hyperorality, food refusal, pica, excessive eating | Medication effects, depression, dysphagia |
Non-Pharmacological Management — FIRST-LINE
Non-pharmacological approaches should always be the first step in managing BPSD. The DICE approach (Describe, Investigate, Create, Evaluate) provides a structured framework.
1
Assess and address unmet needs
Systematic assessment for pain (PAINAD scale), constipation (use laxatives if on opioids), urinary retention, infection, dehydration, sensory deficits (hearing aids, glasses), and environmental factors.
2
Environmental modification
Reduce noise and overstimulation. Ensure adequate lighting (reduce shadows). Maintain consistent routine. Use orientation cues (clocks, calendars). Remove hazards. Minimise room changes in hospital.
3
Person-centred communication
Calm, simple language. Avoid arguing or correcting. Validate the person's emotional experience. Use distraction and redirection. Identify and respect lifelong preferences and routines.
4
Activity and social engagement
Structured meaningful activities based on life history and preferences. Music therapy (strong evidence for agitation reduction). Art therapy. Pet therapy. Gentle exercise. Snoezelen/sensory stimulation rooms in RACF.
5
Pharmacological review
DEPRESCRIBE anticholinergic medications (antihistamines, tricyclics, bladder antispasmodics, antipsychotics). Review polypharmacy. Use the Anticholinergic Cognitive Burden (ACB) scale to identify contributing medications.
Pharmacological Management of BPSD — When Non-Pharmacological Approaches Are Insufficient
Antipsychotic black-box warning: Atypical antipsychotics are associated with a 1.6–1.7× increased risk of death in elderly patients with dementia (FDA/EMA/TGA warnings). Use ONLY when BPSD pose a serious risk to the person or others, at the lowest effective dose, for the shortest possible duration, with documented informed consent, regular review (minimum every 3 months), and attempted dose reduction/cessation at least every 6 months.
Risperidone (low dose)
Risperdal® · Atypical antipsychotic
Indication
Short-term treatment of aggression and psychosis in moderate-to-severe AD (up to 12 weeks). Only antipsychotic with PBS authority for BPSD in Australia.
Adult dose
0.25 mg PO nocte → titrate to 0.5 mg–1 mg/day. Max 2 mg/day but try to stay ≤1 mg/day in elderly.
Key risks
Cerebrovascular events (1.5–3× risk), falls, extrapyramidal symptoms, QTc prolongation, metabolic effects, sedation. Increased mortality risk in dementia.
PBS status
Authority Required — For treatment of psychotic symptoms/aggression in dementia when non-pharmacological measures have been trialled and failed
Citalopram
Cipramil® · SSRI antidepressant
Indication
Agitation in AD (off-label but well-evidenced — CITAD trial). Also first-line for comorbid depression in AD.
Adult dose
10 mg PO mane → 20 mg mane after 1 week if tolerated. Max 20 mg/day in elderly (FDA QTc warning above 20 mg in >60 years). Duration: ongoing if effective.
Key risks
QTc prolongation (dose-dependent, ECG if dose >20 mg or risk factors). Hyponatraemia (SIADH — check sodium at 2–4 weeks). Falls. Bleeding risk (antiplatelet effect).
PBS status
PBS General Benefit (for depression indication). Off-label for agitation — authority not specifically required but document rationale.
Trazodone
Molipaxin® · Serotonin modulator / sedating antidepressant
Indication
Sleep disturbance, agitation, and anxiety in AD (off-label). Often used as a gentler alternative to antipsychotics.
Adult dose
25–50 mg PO nocte → titrate to 50–100 mg nocte. Rarely need >150 mg/day.
Key risks
Sedation, orthostatic hypotension, priapism (rare). Avoid in severe hepatic impairment.
PBS status
PBS General Benefit
Prazosin (for nightmares)
Minipress® · α1-adrenergic antagonist
Indication
Nightmares, nocturnal agitation, PTSD-related sleep disturbance in dementia (off-label, emerging evidence).
Adult dose
1 mg PO nocte → titrate by 1 mg weekly → 2–6 mg nocte. Monitor lying/standing BP.
Key risks
First-dose hypotension (start low). Falls risk. Dizziness.
PBS status
PBS General Benefit
Pain Management in Dementia
Undertreated pain is a major and under-recognised driver of BPSD. People with dementia may not be able to articulate pain. Use validated observational tools (PAINAD — Pain Assessment in Advanced Dementia; Abbey Pain Scale) and a stepwise approach.
- Step 1: Regular paracetamol 1 g TDS–QID (preferred first-line; avoid PRN-only dosing in dementia).
- Step 2: Add low-dose buprenorphine transdermal (5–10 μg/hour) if opioid-naïve, or low-dose oxycodone (2.5–5 mg) with bowel care.
- Avoid: NSAIDs in frail elderly (GI bleeding, renal, cardiovascular risks). Avoid tramadol (seizure risk, confusion, serotonergic interactions in SSRI-treated patients). Avoid codeine (CYP2D6 variability, constipation, sedation).
Carer and Caregiver Support
Dementia caregiving is associated with significantly elevated rates of depression, anxiety, social isolation, and physical health problems. Australian data indicate that approximately 50% of primary dementia carers experience clinically significant depression. Systematic caregiver assessment and support is a core component of dementia management.
For the Carer
- Assess carer wellbeing at every visit using validated tools (e.g., Zarit Burden Interview, PHQ-9)
- Provide education on disease trajectory, communication strategies, and behaviour management
- Connect with Dementia Australia: 1800 100 500 (national helpline) — counselling, education programmes, support groups
- Refer to Commonwealth Home Support Programme (CHSP) or Home Care Package (HCP) for in-home assistance
- Respite care options: in-home respite, day respite centres, overnight/short-term residential respite (MBS/My Aged Care access)
- Carer Gateway: 1800 422 737 — online and phone counselling, skills courses, financial support
Medico-Legal and Planning
- Advance care planning: Initiate early in mild AD while the person has capacity. Document preferences for future medical treatment, resuscitation, hospitalisation, and residential care.
- Enduring power of attorney (financial) and enduring guardianship (medical/lifestyle): Recommend formalisation via solicitor while capacity is present.
- Driving assessment: Mandatory reporting varies by state. In most states, doctors must advise patients with moderate or severe dementia to cease driving. Refer for OT driving assessment where available. Austroads guidelines apply.
- Financial vulnerability: People with AD are at increased risk of financial exploitation. Alert family/guardians and refer to appropriate protective services.
- Safety alerts: Consider Safe Return Home / dementia wandering registries. Refer to state/territory dementia behaviour management advisory services (DBMAS).
Key Australian support services: Dementia Australia (1800 100 500) — information, counselling, support groups, education programmes. Carer Gateway (1800 422 737) — respite, counselling, financial support. My Aged Care (1800 200 422) — assessment for aged care services. Dementia Support Australia (DSA) — specialist behaviour support for residential aged care (1800 699 799).
Special Populations
Elderly (≥80 years)
Diagnostic challenge: Cognitive decline may be attributed to "normal ageing." Use age-adjusted normative data for cognitive tests. Comorbidities (vision, hearing, arthritis) may impair test performance — accommodate with modified administration.
Pharmacotherapy: Start at lowest doses. Increased sensitivity to cholinesterase inhibitor GI side effects. Consider rivastigmine transdermal patch for better tolerability. Renal function may affect memantine dosing (eGFR decline common).
Falls risk: Cholinesterase inhibitors and memantine can cause dizziness. Antipsychotics increase falls and fractures. Conduct falls risk assessment (FROP-Com) at every visit.
Polypharmacy: Perform regular medication review. Deprescribe anticholinergic medications. Use the Beers Criteria or STOPP/START tools.
Frailty assessment: Use Clinical Frailty Scale (CFS). Advance care planning is especially important. Integrate palliative care principles early.
Younger-Onset AD (<65 years)
Prevalence: ~28,000 Australians with younger-onset dementia. AD accounts for approximately one-third. Often presents atypically (posterior cortical atrophy, logopenic variant, frontal variant).
Diagnostic delay: Average 2–3 years from symptom onset to diagnosis. Psychiatric misdiagnosis is common (depression, anxiety, stress). Maintain high index of suspicion with persistent cognitive complaints.
Impact: Major financial consequences — loss of earning capacity, mortgage stress, dependent children. NDIS eligibility for people <65. Centrelink Disability Support Pension. Employers may need guidance on workplace modifications.
Genetic counselling: Consider referral, especially with positive family history or very early onset (<50 years). PSEN1, PSEN2, APP genetic testing available through genetics services.
Specific services: Dementia Australia Younger Onset Dementia Key Workers programme. Linking to peer support with age-matched groups.
Renal Impairment
Memantine: Requires dose reduction — eGFR 30–49: max 10 mg/day; eGFR 5–29: 5 mg/day or alternate day. Avoid if eGFR <5.
Galantamine: eGFR 30–59: max 16 mg/day. eGFR <30: avoid.
Donepezil and rivastigmine: No dose adjustment required for renal impairment.
General: Reduced renal clearance may increase antipsychotic exposure. Regular monitoring of renal function (at least every 6–12 months). Adjust all concomitant medications.
Hepatic Impairment
Donepezil: CYP2D6/3A4 metabolised. Use with caution in significant hepatic impairment. No specific dose guidance but monitor closely.
Galantamine: Child-Pugh A: max 16 mg/day. Child-Pugh B–C: avoid.
Rivastigmine: Use with caution; monitor closely in significant hepatic disease.
Antipsychotics: Hepatically cleared — start low, go slow, monitor LFTs.
Immunocompromised
HIV-associated neurocognitive disorder: Consider in differential diagnosis. May co-exist with AD, especially in older PLHIV on long-term ART. HIV testing should be offered in the dementia workup when appropriate.
Organ transplant recipients: Increased dementia risk from calcineurin inhibitor neurotoxicity and accelerated vascular disease. Review immunosuppressive regimen with transplant team.
Infection susceptibility: People with severe AD are at increased risk of aspiration pneumonia, UTIs, and skin infections regardless of immune status. Consider immunisation optimisation (influenza, pneumococcal, COVID-19, shingles).
Pregnancy (Younger-onset, rare)
Context: AD in women of childbearing age is exceedingly rare. If pregnancy occurs in a woman on cholinesterase inhibitors or memantine, seek specialist advice immediately.
Cholinesterase inhibitors: Limited human data. Animal studies suggest potential fetal effects. Risk–benefit discussion required — likely recommendation to discontinue during pregnancy and breastfeeding.
Memantine: Limited human data. Animal studies show potential developmental effects. Discontinuation advised during pregnancy.
Contraception: Discuss family planning in women of reproductive age with early-onset AD.
Investigations
Cognitive Assessment Tools
Essential
Montreal Cognitive Assessment (MoCA)
Sensitivity ~90% for MCI, ~100% for mild AD. Better sensitivity than MMSE for MCI and mild dementia. Takes ~10 minutes. Available free at mocatest.org. Cut-off: <26/30 (adjust for education, age, culture). Also available in 5-minute telephone version (MoCA-5T) for telehealth.
Essential
Mini-Mental State Examination (MMSE)
Widely used. Less sensitive for MCI. Cut-off: <24/30 (adjust for education and age). Takes ~10 minutes. Note: copyright restrictions — use MoCA as preferred alternative where available.
Available
General Practitioner Assessment of Cognition (GPCOG)
Designed for Australian GPs. Takes ~4 minutes. Includes informant component. Good sensitivity for dementia. Free to use.
Available
Rowland Universal Dementia Assessment Scale (RUDAS)
Culturally fair cognitive screening tool — less affected by education and language. Recommended for CALD (culturally and linguistically diverse) populations and Aboriginal and Torres Strait Islander peoples. Free to use. Takes ~10 minutes.
Specialist
Neuropsychological assessment
Comprehensive battery (typically 2–3 hours) by clinical neuropsychologist. Essential for atypical presentations, diagnostic uncertainty, MCI confirmation, medicolegal assessments. MBS Item 10968 (GP referral under chronic disease management or specialist referral).
Functional and Behavioural Assessment
Essential
Functional Activities Questionnaire (FAQ) or ADCS-ADL
Informant-rated assessment of instrumental and basic ADLs. Essential for determining severity and care needs.
Essential
Neuropsychiatric Inventory (NPI / NPI-12)
Informant-rated assessment of BPSD — 12 domains including delusions, hallucinations, agitation, depression, anxiety, apathy, irritability, motor disturbance, night-time behaviours, appetite changes. Guides treatment planning.
Available
Depression screening: GDS-15 (Geriatric Depression Scale) or PHQ-9
Depression is common in early AD and may co-exist with and accelerate cognitive decline. GDS-15 preferred in dementia (avoids somatic items that overlap with medical comorbidities).
Available
PAINAD (Pain Assessment in Advanced Dementia)
Observational pain scale for people who cannot self-report. Assess breathing, negative vocalisation, facial expression, body language, consolability. Use at every visit for moderate-to-severe AD.
Aboriginal and Torres Strait Islander Health
Aboriginal and Torres Strait Islander Health Considerations
Significant health inequity: Aboriginal and Torres Strait Islander Australians experience dementia at 3–5 times the age-standardised rate of non-Indigenous Australians (AIHW, 2023). Onset is often 10 years earlier, and younger-onset dementia prevalence is disproportionately high. Cardiovascular risk factors (type 2 diabetes, hypertension, chronic kidney disease, rheumatic heart disease) contribute to vascular and mixed dementia burden. Under-diagnosis and delayed referral remain significant concerns.
Prevalence and Risk Factors
- Age-standardised dementia prevalence: ~13% in Aboriginal and Torres Strait Islander peoples aged ≥45 years vs ~3% in non-Indigenous Australians (NATSIHS data).
- Mean age of dementia onset approximately 53–58 years in some remote communities — a decade earlier than non-Indigenous Australians.
- High prevalence of modifiable risk factors: type 2 diabetes (which increases dementia risk 1.5–2×), cardiovascular disease, chronic kidney disease, rheumatic heart disease, head injury, and harmful alcohol use.
- Concepts of dementia, cognitive decline, and ageing may differ significantly from Western biomedical frameworks. Many Aboriginal and Torres Strait Islander languages do not have a direct word for "dementia."
Culturally Safe Assessment
Key research: The landmark Koori Dementia Study (Smith et al., 2008, 2010) established the epidemiology of dementia in Aboriginal communities in the Kimberley region. The DEEP (Dementia Education and Engagement Program for Aboriginal and Torres Strait Islander communities) continues to build culturally safe assessment and care capacity. The AIHW report "Dementia in Australia" (2023) provides comprehensive Indigenous-specific data.
📚 References
- 1. Australian Institute of Health and Welfare (AIHW). Dementia in Australia. Cat. no. DEM 1. Canberra: AIHW; 2024. Available from: aihw.gov.au.
- 2. Dementia Australia. Key facts and statistics about dementia. Melbourne: Dementia Australia; 2024. Available from: dementia.org.au.
- 3. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535–562.
- 4. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9–21. (Clarity AD trial)
- 5. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512–527.
- 6. Dementia Australia. Understanding dementia: An introduction to dementia for health professionals. Melbourne: Dementia Australia; 2023.
- 7. Smith K, Flicker L, Lautenschlager NT, et al. High prevalence of dementia and cognitive impairment in Indigenous Australians. Neurology. 2008;71(19):1470–1473.
- 8. Smith K, Flicker L, Sherriff D, et al. Dementia in rural and remote Australia: the KICA Screen. Int Psychogeriatr. 2010;22(5):762–768.
- 9. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–446.
- 10. Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–691.
- 11. Royal Australian College of General Practitioners (RACGP). Management of behavioural and psychological symptoms of dementia: a guide for general practitioners. Melbourne: RACGP; 2023.
- 12. Australian Commission on Safety and Quality in Health Care (ACSQHC). NSQHS Standards: Comprehensive Care Standard — caring for people with cognitive impairment. Sydney: ACSQHC; 2021.
- 13. Cummings J, Lee G, Nahed P, et al. Alzheimer's disease drug development pipeline: 2024. Alzheimers Dement (N Y). 2024;10(1):e12465.
- 14. Brodaty H, Burns K. Nonpharmacological management of apathy in dementia: a systematic review. Am J Geriatr Psychiatry. 2012;20(7):549–564.
- 15. Austroads. Assessing fitness to drive. 5th ed. Sydney: Austroads; 2022. Available from: austroads.com.au.